CA-GILEAD-SCIENCES
9.9.2019 13:32:14 CEST | Business Wire | Press release
Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS Foundation today announced the launch of the ground-breaking RADIAN initiative at the Fast-Track Cities 2019 conference in London. RADIAN seeks to meaningfully address new HIV infections and deaths from AIDS-related illnesses in Eastern Europe and Central Asia (EECA). RADIAN builds on the existing collaboration between the Foundation and Gilead in the EECA Key Populations (EECAKP) fund, leveraging both organizations’ greater understanding of the region’s needs to drive forward bold and meaningful action to address specific challenges.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190909005498/en/
“Every day, more than 400 people in EECA become infected with HIV and 100 die from AIDS,” said Sir Elton John, Founder, Elton John AIDS Foundation. “My Foundation’s work in establishing the Eastern Europe and Central Asia Key Populations (EECAKP) fund with Gilead and others a couple of years ago forcefully underscored for us the need to drastically expand our efforts in the region. So, I’m delighted that the Foundation is once again working with Gilead through RADIAN to provide much-needed support and funding to reverse trends and reach some of the world’s most vulnerable people. Together, we can create change, save lives and ensure no one is left behind in the fight to end the epidemic.”
Addressing the epidemic in EECA is imperative to the global effort to eliminate HIV/AIDS. According to UNAIDS, while rates of new HIV infections and deaths from AIDS-related illnesses are now decreasing globally, EECA is one of the few regions where HIV is on the rise and deaths from AIDS have increased by approximately 300 percent in the last 20 years.
“Gilead and the Foundation share a vision to end the HIV epidemic. Through RADIAN, we aim to reach marginalized populations in the EECA region and work with local organizations to address some of the challenges they face,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “RADIAN will help to provide the funding and support for the HIV response that have historically been lacking in the region. There are more than one million people living with HIV in EECA who need access to appropriate care. This needs to be urgently addressed through education, community empowerment and novel partnerships such as this.”
The RADIAN initiative is comprised of two key elements, the RADIAN “Model Cities” program and the RADIAN “Unmet Need” fund. By adapting a dual-track program, RADIAN can direct resources to communities in need that are immediately ready to scale interventions through targeted funding, while simultaneously building capacity in others. HIV has high prevalence in communities that often face stigma and have limited access to care. By partnering with local organizations, RADIAN will leverage on-the-ground insights and share the best practices that are needed to make meaningful progress.
The first RADIAN Model City will be Almaty, Kazakhstan. Almaty faces a disproportionately heavy burden of HIV. There are approximately 7,400 people living with HIV in Almaty, and the city has an HIV prevalence that is almost twice the national average. RADIAN will support Almaty in achieving improved HIV outcomes by addressing stigma, strengthening healthcare infrastructure and care models and increasing access to innovation. Additional Model Cities will be announced in 2020.
“We are happy that Kazakhstan will be part of the RADIAN initiative,” said Dr. Bauyrzhan Baiserkin, Director of the Kazakh Scientific Center of Dermatology and Infectious Diseases, based in Almaty. “We have ambitions to reach those that live with or are at risk of HIV to ensure as many of them as possible can get tested and treated so they can live healthy lives. We welcome this support and commitment from the RADIAN initiative to help Kazakhstan continue our progress and ultimately achieve our targets.”
In order to support the rest of the EECA region beyond the selected Model Cities, RADIAN will also implement the Unmet Need fund, to support impactful initiatives in other parts of EECA. Grants will be available for local and regional organizations in EECA who share RADIAN’s vision to address new HIV infections and deaths from AIDS-related illnesses. The Request for Proposals will open in mid-October 2019.
Across both elements, RADIAN aims to contribute measurable changes in HIV incidence, linkage to care and treatment coverage and prevention, to meaningfully address new HIV infections and AIDS-related deaths in EECA. Best practices and learnings from the local implementation of RADIAN over the next five years will be used as a blueprint toward helping change the trajectory of HIV across the region.
About RADIAN
RADIAN is a ground-breaking initiative between the Elton John AIDS Foundation and Gilead Sciences. It aims to meaningfully address new HIV infections and deaths from AIDS-related illnesses in Eastern Europe and Central Asia (EECA), where deaths from AIDS have increased by around 300 percent in the last 20 years.
The Elton John AIDS Foundation and Gilead have an established presence in EECA and extensive experience working effectively with key stakeholders. Through a focused investment of up to $25 million, as well as provision of resources on the ground, RADIAN is a natural evolution of this initiative, leveraging a deep understanding of the EECA community to drive forward the shared ambition to end the HIV epidemic.
Both organizations, as well as potential additional partners in the future, will work together to ensure no one is left behind in the global effort to eliminate HIV/AIDS. Join us in addressing new HIV infections and deaths from AIDS-related illnesses in EECA: www.radianHIV.org .
About the Elton John AIDS Foundation
The Elton John AIDS Foundation is one of the foremost independent AIDS charities in the world. At the Foundation, we believe AIDS can be beaten. We act on that belief by raising funds for evidence-based frontline programs and policies and speaking out with honesty and compassion about the realities of people’s lives. Sir Elton John created the Foundation in 1992. Since then, through hard work and with the help of our network of kind and generous friends and supporters, the Foundation has raised more than $450 million globally to combat stigma, prevent infections, provide treatment and services, and motivate governments to end AIDS. Join us in speaking out, taking action, and continuing the fight against this worldwide pandemic so that no one is left behind.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it is estimated that more than 12 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.
For more information, please visit www.ejaf.org , follow the Foundation on Twitter (@ejaf), Facebook @eltonjohnaidsfoundation and Instagram (@ejaf).
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005498/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION14.7.2026 14:00:00 CEST | Press release
Non-arteritic anterior ischemic optic neuropathy (NAION) is a loss of blood flow to the optic nerve which causes spontaneous and rapid vision loss, for which there are currently no FDA-approved treatments. Given the substantial unmet need for effective treatments in NAION, in October 2025, Dompé was awarded a Commissioner’s National Priority Review Voucher (CNPV) by the US FDA to accelerate a potential Biologics License Application for intranasal nerve growth factor (NGF) in NAION. Dompé, a biopharmaceutical company with operations in Italy and the US, announced the first patient has been enrolled in a Phase 3 study of cenegermin-bkbj for the treatment of non-arteritic anterior ischemic neuropathy (NAION). Involving more than 130 centers globally, the Phase 3 trial, “Galassia-NAION-301” is a multicenter, double-blind study comparing cenegermin-bkbj against placebo in improving vision loss caused by NAION. “Our NGF R&D program continues to accelerate with our third clinical study of 202
CE-IVDR Mark for Hologic’s Aptima® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening14.7.2026 14:00:00 CEST | Press release
New indication in the European Union and the UK offers alternative method of screening especially for women who are not currently participating Hologic, Inc. announced today that its Aptima® HPV Assay received an expanded CE-IVDR marking in the European Union and the UK and is now approved for self-collected vaginal samples using the Aptima Multitest Specimen Collection Kit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714358586/en/ Hologic’s Aptima® HPV Assay and Aptima Multitest Specimen Collection Kit Cervical cancer is the fourth most common cancer in women but is largely preventable through HPV vaccination and regular screening.1 Evidence shows that organized screening and early detection reduces deaths from cervical cancer, with mortality reduction rates in Europe ranging from 41% to 92%.2 However, even in countries with an established cervical screening program, screening participation rates vary widely, from 25%
Cover Genius Raises USD $100M Backed by Vista Credit Partners, Reaching USD $1.9 Billion Valuation as it Advances AI-First Platform and Global Expansion14.7.2026 14:00:00 CEST | Press release
Accelerating the AI roadmap and next era of embedded protection Cover Genius, the global infrastructure for embedded protection, today announced a USD $100M capital raise, backed by Vista Credit Partners, a subsidiary of Vista Equity Partners and strategic financing partner focused on enterprise software. The raise values the business at USD $1.9 billion, advancing a new chapter for the company. Cover Genius operates a B2B2C embedded protection platform that connects 200+ partners with 50+ global insurance carriers to protect over 70 million end customers at the point of sale across travel, retail, ticketing and logistics. Unlike traditional insurers, Cover Genius dynamically adapts product design, pricing, and presentation in real time to match each merchant's unique customer journey and geography mix. “We’ve spent more than a decade building the trust layer the world’s largest digital companies rely on to protect their customers. Today’s raise is about broadening possibilities: movin
Esri to Debut the Power of Where Collection at 2026 Esri User Conference14.7.2026 14:00:00 CEST | Press release
New Titles Expand on Landmark Work to Showcase How GIS Drives Better Decisions Across Water and Land Management Esri will debut the Power of Where Collection at the 2026 Esri User Conference. The collection builds on the 2024 book The Power of Where by Jack Dangermond, extending its ideas into real-world GIS applications. New titles in the collection highlight GIS uses in water forecasting, land records, infrastructure planning, and economic development. The series demonstrates how spatial analysis helps organizations address challenges including sustainability, climate resilience, and governance. Esri, the global leader in location intelligence, will debut the Power of Where Collection at the 2026 Esri User Conference in July. The collection builds on the ideas introduced in The Power of Where: A Geographic Approach to the World's Greatest Challenges, by Esri president Jack Dangermond, published in 2024. The new collection expands these foundational concepts into focused, real-world a
Esri Introduces ArcGIS for ServiceNow, Bringing Location Intelligence into Everyday Enterprise Workflows14.7.2026 14:00:00 CEST | Press release
New Integration Connects Platforms, Enabling Real-Time Mapping Directly Within Existing Systems Esri is launching ArcGIS for ServiceNow, an integration that connects ServiceNow, the AI control tower for business reinvention, with ArcGIS, bringing location intelligence into everyday enterprise workflows. The solution supports organizations across commercial, government, health care, utilities, energy, telecom, and other sectors. Users can visualize incidents, assets, work orders, facilities, and other business data on maps in real time within ServiceNow or ArcGIS, improving decision-making and operational efficiency. The integration eliminates data duplication by enabling seamless data sharing between systems, bridging business records with geographic context. ArcGIS for ServiceNow will debut in beta shortly after Esri User Conference. Esri, the global leader in geographic information system (GIS) technology, has announced ArcGIS for ServiceNow, connecting the two platforms for the firs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom